The Global Liquid Biopsy Market 2018 To 2022 Business Overview:

Liquid biopsy is one of the promising non-invasive methods for the diagnosis of cancer. It involves the sampling of tissue in the liquid state. It is a simple and painless method for cancer diagnostic as compared to other diagnostics methods. Therefore, liquid as well as solid biopsy are important for cancer management, and creates excellent growth opportunities in the market. The technology is further applicable for monitoring cardiac and neurologic disease, early detection and evaluation of drug resistance, and prenatal testing. It can now be applied to organ transplant monitoring to bridge the gap between need of new technology, and rising demand.

Driver & Restrains

Increasing awareness about personalized cancer care is ruling the global liquid biopsy market. The market is driven by increasing demand for non-invasive testing, increasing prevalence of cancer, and extensive research and development in the cancer diagnosis and treatment. The market is also driven by number of advantages of liquid biopsies such as quick analysis, identification of specific mutations, low cost, and r less labor required. Furthermore, rising awareness about the diagnosis of various types of cancer stimulate the market growth. However, tumor heterogeneity, remaining the biggest challenge in cancer research, may restrain the growth of the market.

Premium Sample Report Available @ https://www.marketresearchfuture.com/sample_request/710 .

Strategic Approaches by Key Players:

Guardant Health, Inc., Trovagene, Inc., Agena Bioscience Inc. Inc., Admera Health, Biocept, Inc., Circulogene Theranostics,  Inivata Ltd.,  SAGA Diagnostics AB,  Exosome Diagnostics, and Bio-Rad Laboratories, Inc., Agena Bioscience Inc. Inc. are major players in the liquids biopsy market. The key players in the market are focusing on the development of new diagnostics methods and tools, as well as various strategic approaches such as acquisitions, partnership, and collaboration. Fund raising for cancer research is one to the important tasks for the key players to development new diagnostics devices and technologies as well as hold their position in the market.

Guardant Health:

In January 2017, Guardant Health Inc. and MD Anderson and announce partnership to make comprehensive liquid biopsy part of oncology standard of care.

In September, 2016, Guardant Health Inc. expanded the distribution of Guardant360, a genomic cancer test, to gain grounds in the Middle East

In June, 2016, Guardant Health Inc. and Oncotest-Teva entered into a distribution and marketing partnership for Guardant360 in Israel

Bio-Rad Laboratories, Inc.:

In January, 2017, Bio-Rad Laboratories, Inc. acquired RainDance Technologies outreach next generation sequencing applications and strengthen their position in the area of Droplet Digital PCR.

These developments help to determine the growth of the market across the globe, which is significantly lighted by partnerships and geographical expansion.

Cancer Research and Liquid Biopsy:

In February 2016, Circulogene Theranostics entered into a research agreement with the University of Alabama Birmingham (UAB) Comprehensive Cancer Center.

In December 2015, for example, researchers at the San Antonio Breast Cancer Symposium reported the use of cfDNA liquid biopsies to evaluate the prognosis after treatment in breast cancer patients enrolled in two phase III clinical trials.

Additionally, researcher have now successfully applied liquid biopsy to determine the prognosis of patients with colon cancer in phase II. Therefore, increasing applications of liquid biopsy in cancer research is another important driver for the growth of the market.

Game Changers In The Market:

Admera Health:

Admera Health is an advanced molecular diagnostics company focused on personalized medicine and non-invasive cancer testing. In October, 2017, the company the launched laboratory developed test, named, PGxOnco; for cancer supportive care, and LiquidGx, a suite of liquid biopsy based tests for tumor profiling and drug resistance monitoring. This product launches strengthened the position of Admera Health in the market and expand their existing tissue based tumor profiling tests portfolio.

Biocept, Inc.:

Biocept, a molecular diagnostics company, entered into marketing agreement with Miraca Life Sciences to expand target selector testing in the U.S.

Top 10 Players for Global Liquid Biopsy Market:

Guardant Health, Inc., Trovagene, Inc., RainDance Technologies, Inc., Agena Bioscience Inc. Inc., Admera Health, Biocept, Inc., Circulogene Theranostics,  Inivata Ltd.,  SAGA Diagnostics AB,  Exosome Diagnostics and others.

Get Your Customized Report @ https://www.marketresearchfuture.com/sample_request/710 .

 Major TOC For Global Liquid Biopsy Market Research Report- Forecast to 2022:

1 REPORT PROLOGUE

2 INTRODUCTION

2.1 Scope Of Study

2.2 Research Objective

2.3 Assumptions & Limitations

2.3.1 Assumptions

2.3.2 Limitations

2.4 Market Structure

3 RESEARCH METHODOLOGY

3.1 Research Process

3.2 Primary Research

3.3 Secondary Research

4 MARKET DYNAMICS

4.1 Introduction

4.2 Drivers

4.2.1 Comparatively Painless And Non-Invasive Technique

4.2.2 Early Real Time High Precision Detection Of Diseases

4.2.3 Useful For Designing Effective Treatment Strategies Based On The Real Time Molecular Assessment For The Progression Of The Disease

TOC Continued…!

LIST OF TABLES

TABLE 1 GLOBAL LIQUID BIOPSY MARKET BY BIOMARKER TYPE, $ MILLION (2016-2022)

TABLE 2 CIRCULATING TUMOR CELLS (CTCS) MARKET, BY REGION, 2014-2022 ($ MILLION)

TABLE 3 CIRCULATING TUMOUR DNA (CTDNA) MARKET, BY REGION, 2014-2022 ($ MILLION)

TABLE 4 EXTRACELLULAR VESICLES (EVS) MARKET, BY REGION, 2014-2022 ($ MILLION)

TABLE 5 OTHER BIOMARKER TYPE MARKET, BY REGION, 2014-2022 ($ MILLION)

TABLE 6 GLOBAL LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATIONS, 2014-2022 ($ MILLION)

Get Discount @ https://www.marketresearchfuture.com/check-discount/710 .

LIST OF FIGURES

FIGURE 1 GLOBAL LIQUID BIOPSY: MARKET STRUCTURE

FIGURE 2 RESEARCH PROCESS OF MRFR

FIGURE 3 GLOBAL LIQUID BIOPSY: PORTER FIVE FORCES ANALYSIS

FIGURE 4 GLOBAL LIQUID BIOPSY MARKET, BY BIOMARKER TYPE, MARKET SHARE 2016 (%)

FIGURE 5 GLOBAL LIQUID BIOPSY MARKET BY BIOMARKER TYPE, 2016 $ MILLION

FIGURE 6 CIRCULATING TUMOR CELLS (CTCS) MARKET, BY REGION, 2016, $ MILLION

Continued…!

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: [email protected]